Apyx Medical Q3 revenue beats estimates on AYON system demand

Overview

• US surgical aesthetics firm's Q3 revenue rose 9% yr/yr, beating analyst expectations

• Q3 adjusted EBITDA turned positive and beat analyst estimates

• Company reaffirmed full-year 2026 revenue guidance

Outlook

• Apyx Medical reaffirms 2026 revenue guidance of $59.0 mln to $60.0 mln

• Company expects 2026 gross margins between 63% and 65%

• Company lowers 2026 operating expense guidance to $41.0 mln-$42.5 mln from under $45.0 mln

Result Drivers

• SURGICAL AESTHETICS GROWTH - Revenue growth driven by increased sales of AYON system and higher international generator sales

• PRODUCT LAUNCH - Full commercial launch of power liposuction handpiece for AYON system contributed to results

• OEM DECLINE - OEM segment revenue fell due to lower sales volume to existing customers

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Apyx Medical Inc is $6.00, about 131.7% above its November 4 closing price of $2.59

Reuters Recommended Reads

• Nov 4 - Envista Q3 sales rise 3.2%, slightly beat estimates

• Nov 4 - Evolus Q3 revenue rises 13% on toxin and HA gel growth

• Nov 4 - Edwards Lifesciences Q3 sales beat on TMTT portfolio adoption

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)